| |
| |
|
| Insider
Information: |
Hickey Benjamin |
| Relationship: |
Officer |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
14,006 |
|
|
Indirect Shares
|
91 |
|
|
| Direct
Value |
$545,110 |
|
|
|
Indirect Value
|
$4,081 |
|
|
| Total
Shares |
14,097 |
|
|
| Total
Value |
$549,191 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
7
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -116.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Halozyme Therapeutics Inc |
HALO |
SVP, Chief Commerical ... |
2019-10-01 |
13,226 |
|
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2020-01-06 |
0 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
Officer |
2024-02-26 |
780 |
2024-02-26 |
91 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMY |
Bristol-Myers Squibb Co |
President, RayzeBio Org.Office |
• – – |
2024-02-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
91 |
|
% |
|
| BMY |
Bristol-Myers Squibb Co |
President, RayzeBio Org.Office |
• – – |
2024-02-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
780 |
|
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(117,028) |
0 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2024-01-16 |
4 |
S |
$59.02 |
$94,255 |
D/D |
(1,597) |
117,028 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2024-01-08 |
4 |
S |
$58.92 |
$123,143 |
D/D |
(2,090) |
118,625 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2023-12-29 |
4 |
A |
$58.75 |
$999,984 |
D/D |
17,021 |
120,715 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2023-12-13 |
4 |
S |
$56.67 |
$125,807 |
D/D |
(2,220) |
103,694 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
105,914 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
36,394 |
83,617 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2023-01-17 |
4 |
S |
$42.38 |
$66,366 |
D/D |
(1,566) |
47,223 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2023-01-09 |
4 |
S |
$45.37 |
$94,733 |
D/D |
(2,088) |
48,789 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2022-12-21 |
4 |
S |
$40.41 |
$131,266 |
D/D |
(3,248) |
50,877 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
19,149 |
54,125 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2022-01-18 |
4 |
S |
$120.48 |
$75,543 |
D/D |
(627) |
34,976 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,755 |
35,603 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2022-01-07 |
4 |
S |
$135.94 |
$266,984 |
D/D |
(1,964) |
24,848 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2021-03-19 |
4 |
OE |
$114.33 |
$270,848 |
D/D |
2,369 |
29,181 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2021-03-19 |
4 |
AS |
$175.54 |
$417,978 |
D/D |
(2,369) |
26,812 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2021-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,023 |
26,812 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2021-01-07 |
4 |
S |
$215.31 |
$449,525 |
D/D |
(2,078) |
19,789 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
EVP, Chief Commercial Officer |
• – – |
2020-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
21,867 |
21,867 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Commerical Officer |
• – – |
2019-10-01 |
4 |
D |
$15.46 |
$108,065 |
D/D |
(6,990) |
13,226 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, Chief Commerical Officer |
• – – |
2019-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,216 |
20,216 |
0 |
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
